Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 3/20 | 0.44 |
| ▸ | ALPL | P05186 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6622541 | 0.85 | PLA2G10 (0.42) | PLA2G10ALPLCA12CA9HCAR2 | |
| SCHEMBL31067527 | 0.82 | PLA2G10 (0.41) | PLA2G10ALPLHCAR3MAPK1MAPT | |
| SCHEMBL1431995 | 0.82 | ALPL (0.54) | ALPLCA12CA9HCAR2HCAR3 | |
| SCHEMBL4057741 | 0.82 | HCAR2 (0.44) | PLA2G10ALPLHCAR2HCAR3 | |
| SCHEMBL27865500 | 0.81 | ALPL (0.38) | ALPLCA12CA9HCAR2HCAR3 | |
| SCHEMBL15651990 | 0.80 | PLA2G10 (0.41) | PLA2G10ALPLHCAR3MAPK1MAPT | |
| SCHEMBL20015847 | 0.78 | ALPL (0.36) | ALPLCA12CA9HCAR2HCAR3 | |
| SCHEMBL4191221 | 0.78 | MAPK1 (0.61) | ALPLCA12CA9MAPK1MAPT | |
| SCHEMBL22502874 | 0.78 | CHEK1 (0.53) | ALPLCA12CA9HCAR2HCAR3 | |
| SCHEMBL23062896 | 0.77 | PLA2G10 (0.38) | PLA2G10ALPLMAP2K1USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| CN-101675040-A | 2-pyridinecarboxamide derivatives as sodium channel modulators | PFIZER LTD | 2010-03-17 | — | — | CN | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20040152712-A1 | Pharmaceutically active compounds | PFIZER INC. | 2004-08-05 | — | — | US | disclosed |
| EP-1440709-A2 | Combinations comprising cGMP PDE5 inhibitors. | Pfizer Limited (GB) | 2004-07-28 | — | — | EP | disclosed |
| US-20040122010-A1 | Treatment of neuropathy | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
| US-6677335-B1 | PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE DERIVATIVES; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; SEXUAL AND UROGENITAL DISORDERS | PFIZER INC | 2004-01-13 | — | — | US | disclosed |
| CN-1444585-A | Crystalline therapeutic agents | PFIZER LTD (US) | 2003-09-24 | — | — | CN | disclosed |
| US-20030162782-A1 | Treatment of neuropathy | UNITED STATES DEPARTMENT OF ENERGY | 2003-08-28 | — | — | US | disclosed |
| CN-1387531-A | Pyrazolo [4, 3-d ] pyrimidine derivatives | PFIZER LTD (US) | 2002-12-25 | — | — | CN | disclosed |
| EP-1220856-A2 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES | Pfizer Limited (GB) | 2002-07-10 | — | — | EP | disclosed |
| EP-1129706-A2 | Use of cGMP PDE5 inhibitors for the treatment of neuropathy | Pfizer Limited (GB) | 2001-09-05 | — | — | EP | disclosed |
| WO-2001027113-A2 | PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122010-A1 | Treatment of neuropathy | PDE5A, PDE3A, PDE2A | PLA2G10 1121/4885ALPL 3817/4885CA12 4845/4885 |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PLA2G10 1196/4885ALPL 1568/4885CA12 4858/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PLA2G10 1543/4885ALPL 1403/4885CA12 4883/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PLA2G10 1196/4885ALPL 1568/4885CA12 4858/4885 |
| US-20030162782-A1 | Treatment of neuropathy | PDE5A, PDE3A, PDE2A | PLA2G10 1121/4885ALPL 3817/4885CA12 4845/4885 |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PDE5A, PDE3A, PDE3B | PLA2G10 556/4885ALPL 1100/4885CA12 4706/4885 |
| US-20040152712-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | PLA2G10 396/4885ALPL 548/4885CA12 4593/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PLA2G10 1379/4885ALPL 1602/4885CA12 4853/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PLA2G10 1379/4885ALPL 1602/4885CA12 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.